Elizabeth Wright-Harford
Adelaide, SA, Australia
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 9 publications
Advancing drug therapy for brain tumours: a current review of the pro-inflammatory peptide Substance P and its antagonists as anti-cancer agents.
Journal: Recent patents on CNS drug discovery
Published: September 09, 2014
Treatment with the NK1 antagonist emend reduces blood brain barrier dysfunction and edema formation in an experimental model of brain tumors.
Journal: PloS one
Published: December 23, 2013
Evaluating the role of substance P in the growth of brain tumors.
Journal: Neuroscience
Published: June 20, 2013
NK1 receptor antagonists and dexamethasone as anticancer agents in vitro and in a model of brain tumours secondary to breast cancer.
Journal: Anti-cancer drugs
Published: February 15, 2013
The potential for substance P antagonists as anti-cancer agents in brain tumours.
Journal: Recent patents on CNS drug discovery
Published: January 31, 2013
Characterisation of Walker 256 breast carcinoma cells from two tumour cell banks as assessed using two models of secondary brain tumours.
Journal: Cancer cell international
Published: August 11, 2012
Targeting classical but not neurogenic inflammation reduces peritumoral oedema in secondary brain tumours.
Journal: Journal of neuroimmunology
Published: March 30, 2012
Walker 256 tumour cells increase substance P immunoreactivity locally and modify the properties of the blood-brain barrier during extravasation and brain invasion.
Journal: Clinical & experimental metastasis
Published: March 03, 2012
Showing 1-9 of 9
Last Updated: 09/26/2026